Navigation Links
Increasing Diagnosis Rates and Growing Use of Key Agents Such as Pfizer's Lyrica Will Drive Eight Percent Annual Growth in the Fibromyalgia Drug Market Through 2018
Date:7/13/2009

WALTHAM, Mass., July 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased use of key agents such as Pfizer's Lyrica, Eli Lilly/Boehringer Ingelheim's Cymbalta/Xeristar/Ariclaim and Forest Laboratories/Cypress Bioscience's Savella will drive eight percent annual growth in the fibromyalgia market through 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Fibromyalgia also finds that improved diagnosis of the disorder and an expanding drug-treated population will be major market drivers over the next decade, particularly in the U.S. where the greatest growth in diagnosis rates is expected to occur. In the world's major markets, the U.S. accounted for nearly 80 percent of fibromyalgia drug sales in 2008 and will continue to account for more than two-thirds of fibromyalgia drug sales through 2018. Expansion of the market in Europe and Japan will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder.

"Uptake of Lyrica and Cymbalta/Xeristar/Ariclaim will be limited in Europe because both agents received a negative opinion from European regulatory authorities for approval for fibromyalgia," said Decision Resources Analyst Andrea Buurma, B.A. "Although the decision for Savella has not been made yet, regulators' initial refusal to recommend Lyrica's and Cymbalta's marketing authorizations for fibromyalgia indicates more rigorous standards in this region -- it is not clear whether Savella will be able to meet these standards."

The report also finds that, owing to its status as the first-ever approved agent for fibromyalgia and its favorable safety and tolerability profile, Lyrica will remain the dominant U.S. patient and market share leader through 2018 for fibromyalgia treatment. In the U.S., nearly half of the drug-treated fibromyalgia population received Lyrica in 2008, and this patient share will not change through 2018.

Webinar

Members of the media are welcome to attend our upcoming webinar entitled Fibromyalgia: Assessing Current and Future Opportunities in an Expanding Drug-Treated Population. This webinar will be held on Tuesday, July 28 at 2 p.m. EDT. For more information, please contact Gisselle Morales at 781-296-2691 or email her at gmorales@dresources.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Planning for 2020: increasing elderly population poses huge challenges in cancer care
3. US hospitals report infections increasing in frequency and cost
4. Increasing young adult smoking linked to smoking in movies
5. Data Show Vaprisol(R) Is Effective & Safe in Promptly Increasing Serum Sodium Levels in Patients With Euvolemic or Hypervolemic Hyponatremia
6. New Report: Increasing Oregons Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
7. New Report: Increasing Marylands Cigarette Tax Will Reduce Smoking, Save Lives and Save Money
8. Increasing genetic diversity of HIV in the US
9. Studies Show Importance of Language Services on Reducing Disparities, Increasing Quality of Patient Care
10. Kidney Disease Increasing in U.S.
11. Generic Prescription Drugs Show Increasingly Greater Use in Southeastern Pennsylvania
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... ... inspiring stories about real people of God in congregations across the United States. ... a Presbyterian minister ordained in 1964 who has served congregations in seven states ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... ... , ... 82% of adults are unaware of the dangers that infectious bacteria play in mouth ... two times a day that dentists recommend. The ramifications of improper oral upkeep go far ... adults missing 164 million hours of work each year due to dental issues. That is ...
(Date:3/23/2017)... ... 23, 2017 , ... Hakim Unique Group (HUG) just closed ... Healthcom Group (CHG). , The HUG investment is a landmark move, expanding ... CHG is a growing, internationally recognized healthcare management, technology, and services organization. It ...
(Date:3/23/2017)... ... ... After raising more than $1.135 million ($1,479,231 AUD) from nearly 20,000 backers ... crowdfunding history, has established a U.S. Headquarters in New York City, FaceCradle USA, LLC, ... excited to be operating on U.S. shores, where most of our initial crowdfunding backers ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... capillary electrophoresis market to grow at a CAGR of 7.06% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:3/23/2017)... Newborns are highly vulnerable to infections ... their young immune systems typically mount weak antibody ... achieving strong vaccine responses in newborn animals, including ... trials — by adding compounds known as adjuvants ... papers, they also describe improved adjuvant formulations that ...
(Date:3/23/2017)... , March 23, 2017 ... from the TACTI-mel trial of IMP321 in combination with ... the first (1mg/kg) cohort experiencing a complete response. Recruitment ... cohort is expected to be fully recruited by Q317. ... the AIPAC breast cancer study are expected mid-year (recruitment ...
Breaking Medicine Technology: